Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $10.80 Consensus PT from Analysts

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $10.80.

Several equities analysts recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of Sana Biotechnology in a research note on Thursday, April 24th. Jefferies Financial Group assumed coverage on shares of Sana Biotechnology in a research note on Friday, March 14th. They issued a "buy" rating and a $7.00 target price for the company. Finally, Citizens Jmp upgraded shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a research note on Tuesday, March 18th.

Sana Biotechnology Stock Performance

Shares of SANA traded down $0.11 during trading hours on Wednesday, hitting $2.16. The stock had a trading volume of 4,703,731 shares, compared to its average volume of 3,477,170. The firm has a 50-day moving average price of $1.76 and a 200 day moving average price of $2.33. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $8.17. The firm has a market capitalization of $487.03 million, a price-to-earnings ratio of -1.54 and a beta of 1.75.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.02. As a group, analysts predict that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

A number of large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its position in Sana Biotechnology by 5.4% during the first quarter. Rhumbline Advisers now owns 182,134 shares of the company's stock worth $306,000 after acquiring an additional 9,359 shares during the period. SCS Capital Management LLC acquired a new position in Sana Biotechnology during the first quarter worth $137,000. Woodline Partners LP raised its position in Sana Biotechnology by 13.1% during the first quarter. Woodline Partners LP now owns 780,656 shares of the company's stock worth $1,312,000 after acquiring an additional 90,515 shares during the period. Clearline Capital LP acquired a new position in Sana Biotechnology during the first quarter worth $690,000. Finally, AQR Capital Management LLC raised its position in Sana Biotechnology by 49.8% during the first quarter. AQR Capital Management LLC now owns 573,146 shares of the company's stock worth $963,000 after acquiring an additional 190,483 shares during the period. 88.23% of the stock is currently owned by institutional investors and hedge funds.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.